Optimized AFO Care For Children With Cerebral Palsy. (OPTI-CARE)
3 de setembro de 2026 atualizado por: Merel Brehm, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Effectiveness And Costeffectiveness Of Optimized Ankle Foot Orthosis Care For Children With Cerebral Palsy.
Ankle-foot orthoses (AFOs) are widely prescribed in children with cerebral palsy (CP) to improve their gait, enhance mobility and prevent secondary complications during growth. However, in the Netherlands there is considerable variation in how AFO treatment is provided, and AFOs are not always optimally effective.
In adults with neuromuscular disorders, it has been proven that optimized orthotic care delivered according to a standardized protocol reduces practice variation and is more effective in achieving individual treatment goals and improving patient satisfaction than usual orthotic care. For children with CP, it is expected that orthotic care based on a similarly standardized and optimized approach, will support better decision-making regarding the most appropriate orthosis and improve the overall AFO care process. In addition, such an approach may reduce healthcare costs compared to current AFO care, for example by reducing the need for consultations with other healthcare professionals.
The aim of this study is to develop a new approach to AFO treatment in children with CP. This will be done by developing a standardized protocol that provides guidelines and instructions for healthcare professionals on key aspects of AFO selection, user training and evaluation. First, the effects of current AFO care will be evaluated in a group of 43 children with CP. After development of the new optimized protocol, the effects of optimized AFO care will be evaluated in a second group of 43 children with CP. The investigators will compare the attaining of personal treatment goals at 3 months follow-up between optimized AFO care and usal AFO care, and assess the cost-effectiveness of both interventions.
Visão geral do estudo
Status
Ainda não está recrutando
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
86
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Dr. Merel-Anne Brehm, PhD
- Número de telefone: 020 566 9111
- E-mail: m.a.brehm@amsterdamumc.nl
Locais de estudo
-
-
North Holland
-
Amsterdam, North Holland, Holanda, 1105 AZ
- Amsterdam UMC, location AMC
-
Contato:
- Dr. Merel-Anne Brehm, PhD
- Número de telefone: 020 566 3345
- E-mail: m.a.brehm@amsterdamumc.nl
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Diagnosis of cerebral palsy
- Age range from independent walking onset up to 18 years
- Ability to walk independently with or without a walking aid (e.g., a walker)
- Indication for a first or repeated prescription of AFO for daytime use to improve gait function
Exclusion Criteria:
- Orthopaedic or neurosurgical surgery within the past 6 months (e.g., SDR)
- Child and parent do not speak Dutch
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Usual AFO care
Usual AFO care, is the current AFO care given in the different participating rehabilitation centres according to their own approach.
|
|
|
Experimental: Optimized AFO care
Optimized AFO care, this group receives optimized AFO care following the new standardized protocol that will be developed during this study.
|
Standardized protocol for decision making in AFO care
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline to 3 months follow-up in attainment of individual treatment goals
Prazo: Individual treatment goals will be established at baseline, and at 3 months and 6 months after the AFO has been delivered.
|
The individual treatment goals will be set and evaluated using goal attainment scaling (GAS).
Goals will be defined at the activity and/or participation level and are rated on a scale ranging from -3 to +2. (where the current situation is defined as -2 and the desired attainment goal as 0).
Attainment of the goals at 3 and 6 months follow-up will be scored as -3 for worsened, -2 for unchanged, -1 for somewhat less than expected, 0 for expected outcome, +1 for somewhat more than expected, and +2 for much more than expected.
|
Individual treatment goals will be established at baseline, and at 3 months and 6 months after the AFO has been delivered.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline to 3 months follow-up in gait function
Prazo: At baseline, and 3 and 6 months after the AFO has been delivered.
|
Gait function will be evaluated with a 10-meter walking test and simultaneous video assessment.
Besides walking speed, the following outcomes will be assessed: foot contact at initial contact, knee angle during midstance, foot contact during midstance, minimal knee angle during late stance, clearance at early swing, and clearance at late swing
|
At baseline, and 3 and 6 months after the AFO has been delivered.
|
|
Orthosis satisfaction at 3 months follow-up, assessed with the Dutch version of the client satisfaction with device (D-CSD) module of the OPUS questionnaire
Prazo: At baseline (only for participants who already wear an AFO), and 3 and 6 months after the AFO has been delivered.
|
The D-CSD contains 10 items rated on a 5-point Likert scale ranging from 0; 'strongly disagree' to 4; 'strongly agree', with a total score ranging from 0-40.
|
At baseline (only for participants who already wear an AFO), and 3 and 6 months after the AFO has been delivered.
|
|
Experiences of participants with the provided AFO treatment at 3 months follow-up
Prazo: 3 months after the AFO has been delivered.
|
Experiences of participants with the AFO treatment will be explored with a semi-structured interview.
|
3 months after the AFO has been delivered.
|
|
Orthosis satisfaction at 3 months follow-up, assessed with the Dutch version of the Quebec User Evaluation of Satisfaction with Assistive Technology (D-Quest) questionnaire
Prazo: At baseline (only for participants who already wear an AFO), and 3 and 6 months after the AFO has been delivered.
|
The D-Quest assesses the satisfaction with aspects related to the orthotic device and the provided services.
The questionnaire consists of 9 questions about characteristics of the orthotic device, all scored on a 5-point scale, ranging from 'not satisfied at all' to 'very satisfied'.
Total scores for the device component range from 9 to 45, with higher scores indicating greater satisfaction.
|
At baseline (only for participants who already wear an AFO), and 3 and 6 months after the AFO has been delivered.
|
|
Change from baseline to 3 months follow-up in quality of life on the EuroQol 5-dimension 5-level (EQ-5D-5L)
Prazo: At baseline, and 3 and 6 months after the AFO has been delivered.
|
The EQ-5D-5L contains five questions about mobility, self-care, usual activities, pain/discomfort and anxiety and depression scored on a 5-point scale indicating the degree of problems with each dimension and one question about experienced health scored on a 0-100 visual analogue scale.
|
At baseline, and 3 and 6 months after the AFO has been delivered.
|
|
Change from baseline to 3 months follow-up in perceived pain and stability, assessed with a questionnaire
Prazo: At baseline, and 3 and 6 months after the AFO has been delivered.
|
A 10-point Numeric Rating Scale (NRS) where for pain 0 is 'no pain at all' and 10 is 'unbearable pain', and for stability 0 is 'not stable at all' and 10 is 'extremely stable'.
|
At baseline, and 3 and 6 months after the AFO has been delivered.
|
|
AFO usage at 3 months follow-up, assessed with a questionnaire
Prazo: At baseline (only for participants who already wear an AFO), and 3 and 6 months after the AFO has been delivered.
|
A questionnaire containing items about how often the child wears the AFO inside and outside the house and for how many hours per day and how many days per week.
|
At baseline (only for participants who already wear an AFO), and 3 and 6 months after the AFO has been delivered.
|
|
Adverse events with the AFO
Prazo: Up to 6 months follow-up
|
The following adverse events reported by the participant or observed by the investigator or orthotist will be recorded; pressure sores, abrasions, pain due to the AFO, and material damage of the AFO
|
Up to 6 months follow-up
|
|
Health care costs and societal costs assessed with a cost-questionnaire
Prazo: Directly post-intervention when the AFO is delivered, and 3 and 6 months after the AFO has been delivered.
|
The parents and children fill out a cost questionnaire to record health care costs related to AFO care, as well as societal costs.
|
Directly post-intervention when the AFO is delivered, and 3 and 6 months after the AFO has been delivered.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Investigadores
- Diretor de estudo: Prof. dr. Annemieke Buizer, MD PhD, Amsterdam UMC, location Vumc, Amsterdam, Noord-Holland 1081 HV
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Wingstrand M, Hagglund G, Rodby-Bousquet E. Ankle-foot orthoses in children with cerebral palsy: a cross sectional population based study of 2200 children. BMC Musculoskelet Disord. 2014 Oct 2;15:327. doi: 10.1186/1471-2474-15-327.
- VAN Duijnhoven E, Koopman FS, Tuijtelaars J, Altmann V, VAN Dongen JM, Janse M, Nollet F, Brehm MA. Specialized orthotic care to improve functioning in adults with neuromuscular disorders: results of an open-label blinded end-point randomized controlled trial. Eur J Phys Rehabil Med. 2025 Jun;61(3):496-508. doi: 10.23736/S1973-9087.25.08770-2.
- Brehm MA, Harlaar J, Schwartz M. Effect of ankle-foot orthoses on walking efficiency and gait in children with cerebral palsy. J Rehabil Med. 2008 Jul;40(7):529-34. doi: 10.2340/16501977-0209.
- Morris C, Newdick H, Johnson A. Variations in the orthotic management of cerebral palsy. Child Care Health Dev. 2002 Mar;28(2):139-47. doi: 10.1046/j.1365-2214.2002.00259.x.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de setembro de 2026
Conclusão Primária (Estimado)
1 de novembro de 2030
Conclusão do estudo (Estimado)
1 de setembro de 2031
Datas de inscrição no estudo
Enviado pela primeira vez
10 de agosto de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
3 de setembro de 2026
Primeira postagem (Real)
10 de setembro de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
10 de setembro de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
3 de setembro de 2026
Última verificação
1 de setembro de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026.0135
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
SIM
Descrição do plano IPD
Anonymized individual participant data (IPD) and meta data will be made available to third parties via DataverseNL Amsterdam UMC.
Other anonymized IPD and documents will be made available on request including data analysis codes such as SPSS syntaxes or R scripts.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .